Table 2 Summary of deepening responses among patients with a response of very good partial response (VGPR) or partial response (PR) at study entry, by treatment arm, as assessed by the independent review committee.

From: Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

 

Ixazomib, n/N (%)

Placebo, n/N (%)

Relative risk (95% CI)

P value

Patients who deepened to CR/patients in VGPR at study entry

92/213 (43)

48/152 (32)

1.368 (1.034, 1.810)

0.025

Patients who deepened to VGPR or better/patients in PR at study entry

47/89 (53)

12/35 (34)

1.540 (0.935, 2.537)

0.063

Patients with any deepening response/patients in VGPR or PR at study entry

139/302 (46)

60/187 (32)

1.407 (1.102, 1.797)

0.004

  1. P values determined using a Cochran–Mantel–Haenszel test stratified by response at study entry.
  2. CI confidence interval, CR complete response, PR partial response, VGPR very good partial response.
Back to article page